Ninety-eight children aged 1-15 years entered a randomized double-blind study investigating an appropriate dose of oral prednisolone in children admitted to hospital with an acute exacerbation of asthma. None of the children had recently been treated with oral prednisolone. Following admission, the children were randomized to receive prednisolone 0.5 mg kg -', 1 .O mg kg -' or 2.0 mg kg -' in a single daily dose in addition to nebulized bronchodilators. Clinical asthma scores, oxygen saturations, pulse rate, duration of admission and number of nebulizers given were compared in the three treatment groups.
Introduction
The first article showing that corticosteroids are effective in acute severe asthma was published over 40 yr ago (1) . Subsequent studies have confirmed this finding in adults and in children (2) (3) (4) (5) (6) (7) (8) (9) . Courses of oral prednisolone for up to 5 days are recommended in asthma guidelines in adults, the dose being 3MOmg per day. In children the recommended dose is l-2 mg kg -' day -', (10) a commensurately higher dose than in adults. There is no scientific evidence in the medical literature for the use of this dose of prednisolone but concern has been expressed about the possible systemic effects following repeated doses.
For many years in Brighton 2 mg kg -' day -' of prednisolone (11) has been given to children with acute asthma needing hospital admission but parents commented that their children's behaviour was sometimes altered during the prednisolone treatment. They often appeared pale, and some were quiet and unusually reserved while others were very active with a short attention span, these alterations not being associated with concomitant nebulized &agonist inhalations. The prednisolone dose was subse-quently lowered to 1 mg kg -i day ~ ' but the ward staff thought that some children recovered less quickly. Although we believed prednisolone to be effective in acute severe asthma the present study was undertaken to discover whether doses lower than 2 mg kg -' day -i were as effective but would have less potential for unwanted systemic effects. Three doses, 2, 1 and 0.5 mg kg-' day-', were chosen.
Patients and Method
Over a 14 month period all children between the ages of 1 and 15 years, admitted to the Royal Alexandra Hospital with a diagnosis of asthma, were considered for entry into this study. Children under 1 year old were not included because of diagnostic difficulties in this age group and because there is little evidence to demonstrate the efficacy of corticosteroids in asthma at this age (11, 12) . Children were excluded if they were already receiving oral corticosteroids, if they had been prescribed oral corticosteroids within the last 14 days, if they had any significant underlying cardiac or pulmonary disease, if the investigating team was unavailable or if they required intravenous (iv.) therapy at the time of admission. For statistical reasons, children with repeat admissions were only enrolled in the study once. The decision to admit each child was made by the duty senior house officer (SHO) depending on response to 5 mg nebulized salbutamol, according to the hospital protocol.
Once the child had been admitted to the ward, one member of the investigating team (S.L.H.) was contacted. Each patient was assessed by S.L.H. and, if the diagnosis of asthma was confirmed, was invited to join the study. Informed written consent was obtained from the parent or guardian and from the patient where appropriate.
Baseline information was recorded, including age, sex, personal and immediate family history of asthma and other atopic disorders, smoking and any other medical disorders. Severity of asthma was assessed at baseline and on regular occasions following treatment using a previously described clinical asthma score (13) oxygen saturation measurements and pulse rate. Where possible, peak expiratory flow rate (PEFR) and forced expiratory volume in 1 s (FEV,) were measured. The clinical asthma score is based on auscultatory findings, respiratory effort and patient distress, each measured on a O-6 scale giving a maximum of 18 points, with higher scores denoting more severe symptoms. Oxygen saturation was measured using a finger probe with an Ohmeda 3100 saturation monitor during quiet breathing of room air. 'Best of three' measurements of PEFR and FEV, were performed using a mini-Wright peak flow meter and MicroMedical portable printer spirometer. Values for these were compared with reference figures (14) and expressed as percentage of predicted values.
Patients were randomized to receive one of three prednisolone doses: 0.5, 1.0 or 2.0 mg kg -' day -'. Doses were administered once daily, up to a maximum daily dose of 60 mg. Randomization had been previously performed by the hospital pharmacist using sealed envelopes disclosing the required dose. Stratification of randomization was undertaken to ensure approximately equal distributions of girls and boys and of older and younger children between the three treatment groups. The dose of prednisolone was prepared on a different hospital ward and was unknown to the investigating team and to the ward staff where the child had been admitted.
Following administration of the first study dose each child was reassessed for asthma severity by the same investigator (S.L.H.) at 4, 8 and 24 h after treatment and twice daily until discharge. Assessments were made immediately prior to the administration of nebulized bronchodilators and always at least 30 min after the previous nebulized treatment. The decision to change from nebulized to the child's usual inhaled therapy and the decision to discharge the patient was made by the same physician in all cases (S.L.H.). Otherwise, treatment during the admission followed the usual hospital protocol. Nebulized bronchodilators were given by nursing staff every 0.54 h according to need. Prednisolone was given daily throughout the child's hospital stay.
Patients were withdrawn from the study if they subsequently required i.v. therapy for their asthma control. These patients either had oxygen saturations persistently below 91% in air or failed to respond adequately to nebulized therapy. Patients were also withdrawn if their response to therapy was considered to be too slow. Patients withdrawn were subsequently treated with 1 .O mg kg -' day-' of prednisolone according to the usual hospital protocol, with the study team remaining blind to their previous study dose of prednisolone.
Patients were sent home with a 3 day supply of their individual study dose of oral prednisolone, their parents being instructed to give the child single daily doses, up to a maximum of 3 days, if asthma symptoms persisted. All patients were given diaries in which to record day and night symptom scores, use of inhaled &agonists and, when possible best-of-three morning and evening PEFR. These diaries were completed for 14 days then returned by post to the investigating team. Cough and wheeze were scored separately on a l-4 scale (higher scores denoting greater symptoms) and the scores were later summed. For each child, the total cough and wheeze score, the total number of occasions on which relief medication was given and the mean percentage of predicted PEFR were calculated for days l-7 and 8-14 following discharge.
The code for the dosages of prednisolone given to each patient was only broken once all patients had been discharged from hospital and their 2 week follow-up completed.
The study had been granted approval by the local ethics committee.
STATISTICAL ANALYSIS
Sample size calculations were performed using the clinical asthma score 4 h after prednisolone treatment as the main efficacy variable. Assuming a standard deviation of 3.0 (5), a significance level of 5% and a power of 80%, a sample size of 40 in each of the groups would allow the detection of differences of 1.9 between group means as being statistically significant. This was considered to be an appropriate cut-off for clinical importance.
Means for normally distributed data (i.e. oxygen saturations, percentage of predicted PEFR and FEV,, pulse rate and clinical asthma scores) were compared between groups using one-way analysis of variance (ANOVA). Skewed data (for duration of admission, the number of doses of nebulized therapy and of oral prednisolone and the combined cough and wheeze score) were analysed using the Kruskall-Wallis test for non-parametric data (15) . All statistical analyses were performed using a personal computer with SPSS statistical software (16) .
Results
Over the study period 253 children were admitted with a diagnosis of asthma on a total of 320 occasions. Informed parental consent was obtained for 98 children who were subsequently enrolled and randomized. These children had 30 repeat admissions which were excluded from the study. The remaining 155 children were admitted on 192 occasions and were not included for the following reasons. The investigating team was unavailable for 92 admissions. Sixty-seven were already receiving prednisolone prior to admission or had received it within the previous 14 days. Fourteen were principally admitted for a reason other than asthma. Ten refused to give consent and nine required i.v.
-0.8% to 0.6%; pulse rates, -7.7 to 17.7, -15.8 to therapy on admission for their asthma. Table 1 . There were no clinically important differences in demographic characteristics, heart rate, oxygen saturation, clinical asthma score or pulmonary function tests between the three groups at admission. The duration of the current asthma attack was slightly shorter in those randomized to receive 2.0 mg kg -' day -'. PEFR and FEV, were measured in 37 of the 98 children entering the study.
There were no significant differences between the three groups for the median duration of admission or for the median number of doses of nebulized therapy or oral prednisolone given (Table 3) .
No serious short-term side-effects were noted but hyperactivity related to nebulized a-agonist therapy was seen in ten children receiving 0.5 mg kg-i day -', seven receiving 1 .O mg kg ~ i day ~ ' and six receiving 2 mg kg -' Twelve children were withdrawn from the study. In three, the response to therapy after 5 days was considered too slow (one from each treatment group). Five were given i.v. therapy (two received 2 mg kg -' day -', 2 received l.Omgkg-'day-'andonereceived0.5mgkg-'day-'). One child was discovered to have previously received prednisolone from his general practitioner (1.0 mg group). The remaining three, all in the 2 mg prednisolone group, were withdrawn because of vomiting, a diagnosis of pneumonia or the parents withdrew consent. Time after prednisolone administration (h)
Changes over time in mean pulse rate, oxygen saturations and mean clinical score are shown in Figs 1 and 2 . The similarity of the results for the three treatment groups does not suggest any trend in favour of a dose-response relationship. There were no significant differences between treatment group means for any parameter when compared at 4 and 24 h after the first prednisolone dose and at discharge ( Table 2 ). The 95% confidence intervals for the mean differences between children on a 0.5 mg dose and those on a 2 mg dose at 4 h, 24 h and at discharge were as follows: clinical asthma scores, -2.3 to 0.9, -2.4 to 0.2, -1.7 to -0.1; oxygen saturation, 0.2% to 2.2%, -0.4% to 1.6%, A subgroup analysis was performed to examine the pattern of recovery in the children whose asthma was most severe at the time of admission. The 45 children whose admission clinical asthma score values were worse than the whole group median were examined. Their improvement after admission [ Fig. 2(b) ] was similar to that for the whole group [ Fig. 2(a) ].
Diaries were returned by 61 of the 86 children completing the study (71%). The results below are the medians for the three treatment doses, in increasing dose order (i.e. prednisolone 0.5 mg kg day -', 1.0 mg kg -' day -' and then 2.0 kg mg -' day-I). P values are given for the comparison of each parameter between the three treatment groups. Combined scores for cough and wheeze were higher in the first [ re-admitted with an asthma exacerbation within the first 2 weeks after discharge. Two had received 0.5, one had received 1.0 and two had received 2.0 mg kg -' day-' of prednisolone.
Of the 155 children not entering the study, there were 102 boys and 53 girls; the median age was 5.2 years (interquartile range 1.7-7.6 years). The median duration of admission was 41 h (23-69 h). The median number of doses of nebulized &agonist therapy given was 7 (414) and the median number of prednisolone doses given in hospital was 2 (o-3).
Discussion
Over the past 40 years studies comparing corticosteroids with placebo in both children and adults with acute asthma have usually shown corticosteroids to be of benefit. This has resulted in national and international asthma management guidelines recommending short courses of prednisolone during an acute attack of asthma. Although there has been little concern about the short-term systemic absorption of corticosteroids there have been worries that repeated courses may have a long-term effect on both growth and bone biochemistry. It therefore seems pertinent to establish whether lower doses of prednisolone are equally effective. Inconsistent results from previous studies (3,6,17-21) examining steroid dose-response relationships might be explained by differences in the population studied as well as in the methods used. In some, oral corticosteroids were used whereas others used intravenous preparations. There are also differences in the additional use of other asthma therapies particularly theophyllines and &agonists.
This study was specifically designed to evaluate three doses of oral prednisolone in children admitted to hospital with acute asthma in a typical clinical setting as seen in the U.K. Not all children in the U.K. receive maximal &agonist therapy such as half-hourly nebulized salbutamol or i.v. aminophylline. Therefore our bronchodilator therapy was optimized according to the needs of the individual patient. In this way the results of the study should be applicable to children with acute asthma in general and not just to a specific study population. This study is also one of the few to follow patients for 2 weeks after discharge. All clinical assessments were undertaken by the same physician, thus minimizing observer variation in the clinical asthma score and ensuring consistency in clinical decision-making when changing from nebulized to inhaled P-agonist therapy and in the timing of hospital discharge. The investigating physician could not be present 24 h each day but those children who may have been eligible to take part during the study period but were not enrolled had similar characteristics to those who did take part. Thus we feel that the consistency of one investigating physician was preferable to including more children and utilizing more staff which is likely to lead to inaccuracies and differences of interpretation of clinical features.
Although the study sample did not reach the desired size of 120 children, a lower observed standard deviation between clinical asthma scores than the estimate used in the sample size calculation (2.7 compared with 3.0) meant that the study retained the same power to detect a clinically important difference of 1.9 in this variable.
We have been unable to find any statistically significant differences between the three doses of prednisolone used, across a range of clinical outcome measures. Although this randomized study is relatively small, the confidence intervals presented for clinical asthma scores, oxygen saturations and pulse rates give reassurance that important differences have not been missed. Where the extremes of the confidence intervals approached levels of clinical significance, the effect was always in favour of the 0.5 mg group. Furthermore, when a subgroup was analysed which had more clinically severe symptoms on admission than the median for the group as a whole, we were still unable to show any differences between the three prednisolone doses. We are not surprised at these results as it has been known for some time that the dose-response curve to corticosteroid therapy is relatively flat. As stated in local, national and international asthma management guidelines, the aim of treatment is to allow the patients to lead a normal life, free from symptoms using the lowest effective doses of corticosteroids and &-agonist therapy. We believe that this aim also applies to the dose of oral corticosteroids used in acute asthma. Little is known about the long-term consequences of repeated courses of oral prednisolone and because of the multifactorial nature of asthma, a disease with varying symptoms and multiple therapies over long periods of time, it is unlikely that clear associations will be easily identified. Over the past 20 yr acute symptoms of wheeze have increased tremendously, especially in the O-4 year age group. This group accounts for nearly 40% of asthma admissions for all age groups including adults. Therefore many more pre-school children are receiving short courses of prednisolone than in the 1960s and early 1970s.
The results of this study suggest that children over 1 year old suffering from an acute asthma attack not requiring intravenous therapy will respond as effectively to 0.5mgkgg' day-' of prednisolone as they will to higher doses of l.Omgkgg' day-' or 2.0mgkgg' day-' of prednisolone. We recommend the routine dose of prednisolone for use in short courses in children should be 0.5mgkgg'day-'.
